meclinertant
Small moleculeexperimental
Meclinertant (SR-48692) is a drug which acts as a selective, non-peptide antagonist at the neurotensin receptor NTS1, and was the first non-peptide antagonist developed for this receptor. It is used in scientific research to explore the interaction between neurotensin and other neurotransmitters in the brain, and produces anxiolytic, anti-addictive and memory-impairing effects in animal studies. — Wikipedia
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
1
Phase 4
0
Earliest trial started Oct 1, 2002 (NCT00290953)
Timeline
2000s
- Jan 1, 2002
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Neurotensin receptor 1ANTAGONIST
NTSR1 antagonist
Chemistry & pharmacology
Loading structure…
SMILES
COc1cccc(OC)c1-c1cc(C(=O)NC2(C(=O)O)C3CC4CC(C3)CC2C4)nn1-c1ccnc2cc(Cl)ccc12- Mol. weight
- 587.08 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaMeclinertant ↗
- ChEMBLCHEMBL506981 ↗
Also known as
- 2-((1-(7-chloro-4-quinolinyl)-5-(2,6-dimethoxyphenyl)pyrazol-3-yl)carbonylamino)tricyclo(3.3.1.1.(3.7))decan-2-carboxylic acid
- meclinertant
- meclinertant
- meclinertant
- reminertant
- reminertant
- sr48692
- sr48692
- sr48692
- sr 48692
- sr-48692
- sr-48692
- sr-48692
- tricyclo(3.3.1.13,7)decane-2-carboxylic acid, 2-(((1-(7-chloro-4-quinolinyl)-5-(2,6-dimethoxyphenyl)-1h-pyrazol-3-yl)carbonyl)amino)-
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00290953 | Phase 2/Phase 3 (Phase 3) | Oct 1, 2002 | Sanofi |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sanofi | For profit | 1 | 1 | 1 | 2002 |
1 organizations
Page 1 / 1